Laboratory of Veterinary Pharmacology, Division of Veterinary Science, Osaka Prefecture University Graduate School of Life and Environmental Science, Izumisano, Osaka 598-8531, Japan.
Int Immunopharmacol. 2010 Oct;10(10):1261-7. doi: 10.1016/j.intimp.2010.07.007. Epub 2010 Jul 31.
Inflammatory bowel disease (IBD) is characterized by repeated chronic inflammation of the gastrointestinal tract. We have used the complementary model of colonic inflammation to examine the roles of peroxisome proliferator-activated receptor α (PPARα) in colonic inflammation and thus its possible role in IBD. We characterized an innate immune-mediated model of colitis induced by dextran sulfate sodium (DSS). Mice with DSS-induced colitis were injected with Wy-14643 (2 mg/kg) as a PPARα agonist every day from day 0 to day 5. We show that mice given Wy-14643 were less susceptible to experimental acute colitis induced by DSS, and this decreased susceptibility was correlated with decreased production of IFNγ, IL-1β, IL-6, and TNF-α. Our findings suggest that PPARα has a role in controlling colonic inflammation and mucosal tissue homeostasis.
炎症性肠病(IBD)的特征是胃肠道反复发生慢性炎症。我们使用结肠炎症的互补模型来研究过氧化物酶体增殖物激活受体α(PPARα)在结肠炎症中的作用及其在 IBD 中的可能作用。我们描述了葡聚糖硫酸钠(DSS)诱导的结肠炎的固有免疫介导模型。从第 0 天到第 5 天,每天给患有 DSS 诱导结肠炎的小鼠注射 Wy-14643(2mg/kg)作为 PPARα激动剂。我们表明,给予 Wy-14643 的小鼠对 DSS 诱导的实验性急性结肠炎的敏感性降低,这种敏感性降低与 IFNγ、IL-1β、IL-6 和 TNF-α的产生减少相关。我们的发现表明,PPARα在控制结肠炎症和粘膜组织稳态方面发挥作用。